Abstract Background: @entity1 @entity461 ( @entity461 ) (1-34) or teriparatide (TPTD) is an anabolic agent for @entity170 . This recombinant protein stimulates positive bone formation balance and bone remodeling. However, when concomitantly used with antiresorptive (AR) agents, previous studies reported conflicting results in their potential additive and synergistic effects on bone metabolism and @entity79 ( @entity79 ). This study aimed to integrate previous evidence to assess the effect of TPTD monotherapy and the additive effect of TPTD on AR agents in postmenopausal @entity1 with @entity170 . MATERIAL AND METHODS: This meta-analysis identified 9 RCTs from databases. To assess the therapeutic effect on @entity170 , the @entity353 ( @entity353 ) were used to pool the percentage change of @entity79 along with the 95% confidence intervals (CIs). @entity79 of 3 skeletal sites, including lumbar spine, total hip, and femoral neck were assessed. RESULTS: TPTD alone could significantly improve @entity79 of all 3 skeletal sites compared with placebo, although the effect on the femoral neck was less conclusive. The additive effect of TPTD over hormone replacement therapy (HRT) and denosumab ( @entity108 ) agents is evident in all 3 skeletal sites. But TPTD plus @entity561 ( @entity16292 ) did not demonstrate additive effect in total hip and femoral neck. CONCLUSIONS: TPTD alone could significantly improve @entity79 of lumbar spine, total hip, and femoral neck. @entity79 outcomes of concomitant use of TPTD and AR agents are site-dependent and vary depending on the specific AR agent used and the timing of AR therapy initiation.

Single and Combined use of @entity1 @entity461 ( XXXX ) (1-34) on Areal Bone Mineral Density (aBMD) in Postmenopausal @entity1 with @entity170 : Evidence Based on 9 RCTs.

@entity1 :: ('9606', 'Species') :: ['women', 'Human'] @entity108 :: ('CHEBI:34873', 'Chemical') :: ['DEN'] @entity353 :: ('MESH:D015431', 'Disease') :: ['WMDs', 'weighted mean differences'] @entity561 :: ('MESH:D019386', 'Chemical') :: ['Alendronate'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD'] @entity16292 :: ('CHEBI:50878', 'Chemical') :: ['ALN'] @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone']
@entity461 :: (5741,Gene) :: ['PTH']
